600535 Tasly Pharmaceutical Group
- 15.14
- +0.24+1.61%
About Tasly Pharmaceutical Group Company
The company is a leading international enterprise in modern traditional Chinese medicine, and is committed to developing into a leading integrated pharmaceutical and health service solution provider with global influence in China. We are “people-oriented, precise and innovative”, continuously promote the progress of medicine and health care, so that everyone can enjoy the beauty and hope of life. The company's main business is the production and sale of pharmaceuticals. Main products: Compound Danshen Dropping Pills, Serum Nourishing Brain Pellets, Astragalus Ginseng Yiqi Droplets, Temozolomide Capsules (Diqing), Silybin Capsules (Shuilinjia), and Yiqi Fumei for Injection. Corporate honors: “China's Top 100 Pharmaceutical Manufacturing Companies in China”, “2023 China's Top 10 Traditional Chinese Medicine R&D Strength”, “2023 China's Top 50 Pharmaceutical Innovation Enterprises”, “2023 China's Top 100 Pharmaceutical Innovation Enterprises”, “2023 Top 50 Chinese Pharmaceutical Enterprises Comprehensive Competitiveness Index”, “2022 2023 Pharmaceutical Industry Independent Innovation Pioneer Enterprise”, “Top 20 Most Influential and Important Enterprises in International Influence”, “2023 Best Practice Case for Traditional Chinese Medicine Inheritance and Innovation”, “2023 Listed Companies” “ESG Best Practice Case”, “Excellent Brand Enterprise of Chinese Ethnic Medicine in the 2023-2023 Year”, and “First Prize for Digital Quality Management in the Whole Industry Chain of Modern Traditional Chinese Medicine Enterprises”.
Company Profile
Company Executives
- Name
- Position
- Salary
- kaijing yan
- Chairman, Directors, Member of the Nomination, Remuneration and Assessment Committee, Chairman of the Strategy Committee, Audit Committee Member
- 2.81M
- he sun
- Vice Chairman, Directors, Member of the Strategy Committee
- 2.71M
- xiaomeng jiang
- Vice Chairman, Directors, Member of the Strategy Committee
- --
- shuiping zhou
- Directors, Member of the Strategy Committee
- --
- kexin li
- Directors
- --
- jinyong cai
- Directors, General Manager, Member of the Strategy Committee
- 1.36M
- bin zhang
- Independent Directors, Member of the Strategy Committee, Chairman of the Nomination, Remuneration and Assessment Committee
- 200.00K
- aijian wang
- Independent Directors, Member of the Nomination, Remuneration and Assessment Committee, Chairman of the Audit Committee
- 200.00K
- xiutao han
- Independent Directors, Audit Committee Member
- --
- jie yu
- Board Secretary
- 2.48M
- ying zhao
- Securities Affairs Representative
- --
- aichun ju
- Chairman of the Supervisory Board, Auditors
- 874.40K
- jiangshan li
- Auditors
- --
- shunnan zhang
- Auditors
- 1.06M
- jie wei
- Chief Financial Officer
- 1.22M
- zhen wang
- Employee Supervisors
- --
- zhen lu
- Employee Supervisors
- --
Analysis
Price Target
No Data
No Data